4.6 Article

Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome

期刊

MOVEMENT DISORDERS
卷 21, 期 10, 页码 1741-1744

出版社

WILEY
DOI: 10.1002/mds.21001

关键词

tremor; ataxia; fragile X; FXTAS; medications

资金

  1. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274, R01HD036071] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044299, R01NS043532] Funding Source: NIH RePORTER
  3. NICHD NIH HHS [HD36071, HD02274] Funding Source: Medline
  4. NINDS NIH HHS [NS044299, NS43532] Funding Source: Medline

向作者/读者索取更多资源

There is no established treatment for the neurological features of the recently discovered fragile X-associated tremor/ataxia syndrome (FXTAS). Fifty-six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with definite FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall, all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FXTAS can derive improvement from medication treatment for some of their symptoms. (C) 2006 Movement Disorder Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据